(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/059110 A1

(51) International Patent Classification[7]: C07D 403/12, A61K 31/505, 31/53, A61P 35/00

(21) International Application Number: PCT/US01/49367

(22) International Filing Date:
19 December 2001 (19.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/257,526 21 December 2000 (21.12.2000) US
60/262,403 16 January 2001 (16.01.2001) US

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BOLOOR, Amogh** [US/US]; 2302 17th Street, #10, Lubbock, TX 79401 (US). **CHEUNG, Mui** [CN/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **DAVIS, Ronda** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **HARRIS, Philip, Anthony** [GB/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **HINKLE, Kevin** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **MOOK, Robert, Anthony** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **STAFFORD, Jeffery, Alan** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **VEAL, James, Martin** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(74) Agents: **LEVY, David, J** et al.; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

WO 02/059110 A1

(54) Title: PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS

(57) Abstract: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.